Cryoport, Inc. to Post Q2 2025 Earnings of ($0.31) Per Share, Roth Capital Forecasts (NASDAQ:CYRX)

Cryoport, Inc. (NASDAQ:CYRX) – Equities researchers at Roth Capital issued their Q2 2025 earnings estimates for Cryoport in a research report issued to clients and investors on Wednesday, May 8th. Roth Capital analyst R. Baldry forecasts that the company will earn ($0.31) per share for the quarter. The consensus estimate for Cryoport’s current full-year earnings is ($1.42) per share. Roth Capital also issued estimates for Cryoport’s Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.21) EPS.

Cryoport (NASDAQ:CYRX) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.06). Cryoport had a negative return on equity of 11.86% and a negative net margin of 42.69%. The business had revenue of $54.59 million during the quarter, compared to the consensus estimate of $58.78 million. During the same period last year, the business posted ($0.16) earnings per share. The business’s revenue was down 13.1% on a year-over-year basis.

Several other analysts have also weighed in on CYRX. B. Riley lowered shares of Cryoport from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $22.00 to $19.00 in a research note on Friday, May 3rd. Stephens reaffirmed an “equal weight” rating and issued a $17.00 target price on shares of Cryoport in a research report on Wednesday, March 13th. UBS Group increased their price target on Cryoport from $14.50 to $17.00 and gave the stock a “neutral” rating in a report on Friday, March 15th. Jefferies Financial Group began coverage on Cryoport in a report on Thursday, April 4th. They set a “buy” rating and a $21.00 price objective for the company. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $18.00 target price on shares of Cryoport in a report on Wednesday. Six equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $18.25.

Cryoport Trading Up 2.0 %

Shares of CYRX stock opened at $13.46 on Thursday. Cryoport has a fifty-two week low of $9.00 and a fifty-two week high of $23.50. The company has a debt-to-equity ratio of 0.82, a quick ratio of 11.16 and a current ratio of 11.73. The stock has a 50 day simple moving average of $16.78 and a two-hundred day simple moving average of $15.19. The company has a market cap of $661.75 million, a P/E ratio of -6.12 and a beta of 1.60.

Insider Activity at Cryoport

In other Cryoport news, Director Ramkumar Mandalam sold 3,217 shares of Cryoport stock in a transaction on Friday, March 15th. The shares were sold at an average price of $14.68, for a total transaction of $47,225.56. Following the transaction, the director now directly owns 43,187 shares of the company’s stock, valued at approximately $633,985.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Jerrell Shelton sold 2,631 shares of Cryoport stock in a transaction on Monday, March 25th. The stock was sold at an average price of $17.54, for a total transaction of $46,147.74. Following the sale, the chief executive officer now directly owns 692,182 shares in the company, valued at $12,140,872.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ramkumar Mandalam sold 3,217 shares of the company’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $14.68, for a total value of $47,225.56. Following the completion of the transaction, the director now owns 43,187 shares of the company’s stock, valued at approximately $633,985.16. The disclosure for this sale can be found here. In the last three months, insiders sold 73,940 shares of company stock valued at $1,147,538. 10.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Cryoport

A number of hedge funds and other institutional investors have recently made changes to their positions in CYRX. Conestoga Capital Advisors LLC raised its position in Cryoport by 1.0% in the first quarter. Conestoga Capital Advisors LLC now owns 71,417 shares of the company’s stock worth $1,264,000 after acquiring an additional 690 shares during the period. Arizona State Retirement System raised its holdings in shares of Cryoport by 5.4% in the 4th quarter. Arizona State Retirement System now owns 13,665 shares of the company’s stock worth $212,000 after purchasing an additional 696 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Cryoport by 13.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,462 shares of the company’s stock worth $157,000 after purchasing an additional 1,395 shares during the period. Natixis Investment Managers International lifted its stake in Cryoport by 61.5% in the fourth quarter. Natixis Investment Managers International now owns 4,536 shares of the company’s stock valued at $70,000 after purchasing an additional 1,727 shares during the last quarter. Finally, Advisors Capital Management LLC grew its holdings in Cryoport by 2.5% during the third quarter. Advisors Capital Management LLC now owns 78,993 shares of the company’s stock valued at $1,083,000 after purchasing an additional 1,947 shares during the period. 92.90% of the stock is owned by hedge funds and other institutional investors.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.